# US 2014/0155333 A1 · Compositions and methods for cancer treatment using targeted carbon nanotubes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155333 A1
- Document ID: US20140155333A1
- Status: Published application
- Kind: A1
- Application number: 14/100,892
- Filed: 2013-12-09
- Published: 2014-06-05
- Earliest claimed: 2007-02-19
- Assignees: The Board of Regents of the University of Oklahoma
- Applicants: The Board of Regents of the University of Oklahoma
- Inventors: Roger G. Harrison, JR.; Daniel E. Resasco; Luis Filipe Ferreira Neves
- Web page: https://patentgrep.com/patent/US20140155333A1

## CPC

- A61K 41/0052: {Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy}
- A61K 38/1709: {from mammals}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6925: {the form being a microcapsule, nanocapsule, microbubble or nanobubble}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61N 1/406: {using implantable thermoseeds or injected particles for localized hyperthermia (preparations of seeds and particles A61K41/0052)}
- A61N 2/02: using magnetic fields produced by coils, including single turn loops or electromagnets (A61N2/12 takes precedence)
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61N 2005/0659: {infrared}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

Compositions for detecting and/or destroying cancer tumors and/or cancer cells via photodynamic therapy are disclosed, as well as methods of use thereof. The compositions comprise a linking protein or peptide attached to or otherwise physically associated with a carbon nanotube to form a targeted protein-carbon nanotube complex.

## Claims

### Claim 1

A method of treating a cancer tumor or cancer cells in a subject in need of such therapy, the method comprising the steps of:
administering to the subject a composition comprising a protein-carbon nanotube complex, the protein-carbon nanotube complex comprising a protein or peptide operatively attached to a single-walled carbon nanotube (SWNT), wherein the SWNT is semiconducting and nonmetallic and wherein the protein or peptide of the protein-carbon nanotube complex comprises a binding protein or peptide that specifically binds to an external receptor or binding site on a tumor vasculature endothelial cell or on a cancer cell whereby the protein-carbon nanotube complex preferentially binds to the external receptor or binding site on an outer surface of the tumor vasculature endothelial cell or on an outer surface of the cancer cell in the subject; and
exposing the subject to electromagnetic radiation comprising a wavelength absorbable by the SWNT, thereby causing elevation of the temperature of the SWNT of the protein-carbon nanotube complex to a temperature which induces damage to and/or death of the tumor vasculature endothelial cell or cancer cell to which the protein-carbon nanotube complex is bound.

### Claim 2 (depends on 1)

The method of claim 1, wherein the external receptor or binding site is specific for the tumor vasculature endothelial cells or cancer cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein the protein-carbon nanotube complex comprises at least one SWNT having a (n,m) structure selected from the group consisting of (6,5), (7,6), (8,7), (7,5), (8,6), (9,7), and (9,8).

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition comprises a plurality of protein-carbon nanotube complexes having a plurality of absorbable wavelengths.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition comprises at least 25% of a single type of protein-carbon nanotube complex.

### Claim 6 (depends on 1)

The method of claim 1, wherein the SWNT of the composition comprises at least 25% of a single type of (n,m) structure.

### Claim 7 (depends on 1)

The method of claim 1, wherein the external receptor or binding site is at least one of phosphatidylserine, phosphatidylinositol, phosphatidic acid, and phosphatidylglycerol.

### Claim 8 (depends on 1)

The method of claim 1, wherein the binding protein or peptide is attached to the carbon nanotube via a cellulose derivative.

### Claim 9 (depends on 8)

The method of claim 8, wherein the cellulose derivative is carboxymethylcellulose, hydroxymethylcellulose, or hydroxypropylcellulose.

### Claim 10 (depends on 1)

The method of claim 1, wherein the absorbable wavelength is a near-infrared wavelength.

### Claim 11 (depends on 1)

The method of claim 1, wherein the absorbable wavelength is 980 nm±50 nm or 1120 nm±50 nm.

### Claim 12 (depends on 1)

The method of claim 1, wherein the SWNT of the protein-carbon nanotube complex has an S11 transition of at least 50% of background.

### Claim 13 (depends on 1)

The method of claim 1, wherein the protein of the protein-carbon nanotube complex is an annexin.

### Claim 14 (depends on 1)

The method of claim 1, further comprising the step of administering an immunostimulant to the patient.

### Claim 15

A carbon nanotube composition, comprising:
a protein-carbon nanotube complex comprising a protein or peptide operatively attached to a single-walled carbon nanotube (SWNT), wherein the SWNT is semiconducting and nonmetallic, wherein the protein or peptide of the protein-carbon nanotube complex comprises a binding protein or peptide that has binding specific for an external receptor or binding site on a tumor vasculature endothelial cell and/or on a cancer cell, and wherein when a subject to which the composition has been administered is exposed to a light wavelength absorbable by the SWNT, the temperature of the SWNT of the protein-carbon nanotube complex is elevated to a temperature which induces damage to and/or death of the cell to which the protein-carbon nanotube complex is bound.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the protein-carbon nanotube complex comprises at least one SWNT having a (n,m) structure selected from the group consisting of (6,5), (7,6), (8,7), (7,5), (8,6), (9,7), and (9,8).

### Claim 17 (depends on 15)

The composition of claim 15, wherein the composition comprises a plurality of protein-carbon nanotube complexes having a plurality of absorbable wavelengths.

### Claim 18 (depends on 15)

The composition of claim 15, wherein the composition comprises at least 25% of a single type of protein-carbon nanotube complex.

### Claim 19 (depends on 15)

The composition of claim 15, wherein the SWNT of the composition comprises at least 25% of a single type of (n,m) structure.

### Claim 20 (depends on 15)

The composition of claim 15, wherein the absorbable wavelength is 980 nm±50 nm or 1120 nm±50 nm.

### Claim 21 (depends on 15)

The composition of claim 15, wherein the protein of the protein-carbon nanotube complex is an annexin.
